{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:43:04Z","timestamp":1786120984336,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032558","name":"Breakthrough T1D Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001067","name":"Breakthrough T1D","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000943","name":"Commonwealth Scientific and Industrial Research Organisation","doi-asserted-by":"publisher","award":["3-SRA-2023\\u20131296-M-N"],"award-info":[{"award-number":["3-SRA-2023\\u20131296-M-N"]}],"id":[{"id":"10.13039\/501100000943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:29:22Z","timestamp":1778815762000},"page":"379-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Insulin"],"prefix":"10.1016","volume":"55","author":[{"given":"Huajing","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Snaith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/db16-0806","article-title":"Differentiation of diabetes by pathophysiology, natural history, and prognosis","volume":"66","author":"Skyler","year":"2017","journal-title":"Diabetes"},{"issue":"S6","key":"10.1016\/j.ecl.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dom.16460","article-title":"Type 1 diabetes: a guide to autoimmune mechanisms for clinicians","volume":"27","author":"Mauvais","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.ecl.2026.04.001_bib3","series-title":"Glycemic control in the hospitalized patient","first-page":"51","article-title":"Hyperglycemic emergencies: diabetic ketoacidosis and hyperosmolar hyperglycemic state","author":"Corsino","year":"2010"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.001_bib4","article-title":"Frederick G banting (1891-1941): a pioneer in diabetes treatment","volume":"16","author":"Sharma","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.10.1.1","article-title":"Diabetes control and complications trial (DCCT): results of feasibility study. the DCCT research group","volume":"10","year":"1987","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26353","article-title":"Trends and disparities in technology use and glycemic control in type 1 diabetes","volume":"8","author":"Fang","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.2337\/db25-0017","article-title":"The cardiovascular repository for type 1 diabetes (CaRe-T1D): an NIDDK initiative to advance understanding of mechanisms underlying cardiovascular disease in type 1 versus type 2 diabetes","volume":"74","author":"Jones","year":"2025","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/diabetes.47.7.995","article-title":"Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes","volume":"47","author":"Taborsky","year":"1998","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1210\/jcem.87.3.8324","article-title":"Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus","volume":"87","author":"Greenfield","year":"2002","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2004.06.003","article-title":"Glycaemic effects of incretins in type 1 diabetes mellitus","volume":"128","author":"Dupre","year":"2005","journal-title":"Regul Pept"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/pedi.12135","article-title":"Residual C-peptide in type 1 diabetes: what do we really know?: residual C-peptide in T1D","volume":"15","author":"VanBuecken","year":"2014","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc14-2898","article-title":"Glycemic variability and diabetes complications: does it matter? Of course it does","volume":"38","author":"Hirsch","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1210\/endrev\/bnae032","article-title":"Insulin resistance in type 1 diabetes: pathophysiological, clinical, and therapeutic relevance","volume":"46","author":"Apostolopoulou","year":"2025","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2026.04.001_bib14","article-title":"Advancing type 1 diabetes management: integrating novel therapies, technologies, and adjunctive approaches","author":"Snaith","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100469","article-title":"Risk factors, mortality trends, and cardiovascular diseases in people with type 1 diabetes and controls in Sweden: an observational cohort study","volume":"21","author":"Hallstr\u00f6m","year":"2022","journal-title":"The Lancet Regional Health - Europe"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2337\/dc21-1381","article-title":"30-year cardiovascular disease in type 1 diabetes: risk and risk factors differ by long-term patterns of glycemic control","volume":"45","author":"Miller","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"e2032","DOI":"10.1210\/clinem\/dgaa015","article-title":"Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry","volume":"105","author":"Shah","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"The diabetes control and complications trial (DCCT)\/epidemiology of diabetes interventions and complications (EDIC) study research group. intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11892-017-0892-1","article-title":"Biopsychosocial aspects of weight management in type 1 diabetes: a review and next steps","volume":"17","author":"Driscoll","year":"2017","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41366-023-01429-8","article-title":"The emergence of obesity in type 1 diabetes","volume":"48","author":"Kueh","year":"2024","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12645","article-title":"The double burden: navigating type 1 diabetes and obesity","volume":"14","author":"Steenackers","year":"2024","journal-title":"Clinical Obesity"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14794","article-title":"Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes","volume":"39","author":"Carlson","year":"2022","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2337\/diacare.11.7.567","article-title":"Weight gain associated with intensive therapy in the diabetes control and complications trial","volume":"11","year":"1988","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","article-title":"Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT","volume":"280","author":"Purnell","year":"1998","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/1753-0407.13326","article-title":"Small steps forward: adjunctive therapy for T1D","volume":"14","author":"Bloomgarden","year":"2022","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/13591045211026142","article-title":"A review of risk factors associated with insulin omission for weight loss in type 1 diabetes","volume":"26","author":"Hall","year":"2021","journal-title":"Clin Child Psychol Psychiatr"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc15-0753","article-title":"Momentary predictors of insulin restriction among adults with type 1 diabetes and eating disorder symptomatology","volume":"38","author":"Merwin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.peptides.2017.12.001","article-title":"Alpha cell dysfunction in type 1 diabetes","volume":"100","author":"Yosten","year":"2018","journal-title":"Peptides"},{"issue":"16","key":"10.1016\/j.ecl.2026.04.001_bib30","article-title":"Mini-review: glucagon responses in type 1 diabetes \u2013 a matter of complexity","volume":"9","author":"Bisgaard","year":"2021","journal-title":"Phys Rep"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2337\/dc23-0776","article-title":"Residual \u03b2-cell function is associated with longer time in range in individuals with type 1 diabetes","volume":"47","author":"Fuhri Snethlage","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00125-020-05099-3","article-title":"Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes","volume":"63","author":"Gibb","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/nu16010162","article-title":"Postprandial glucose variability following typical meals in youth living with type 1 diabetes","volume":"16","author":"Patton","year":"2024","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.001_bib34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jdi.12360","article-title":"Carbohydrate intake is associated with time spent in the euglycemic range in patients with type 1 diabetes","volume":"6","author":"Ayano-Takahara","year":"2015","journal-title":"J of Diabetes Invest"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.001_bib35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc15-0100","article-title":"Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era","volume":"38","author":"Bell","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1021800","article-title":"Exercise, type 1 diabetes mellitus and blood glucose: the implications of exercise timing","volume":"13","author":"Fitzpatrick","year":"2022","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1932296814566231","article-title":"Physical activity and type 1 diabetes: time for a rewire?","volume":"9","author":"Colberg","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.ecl.2026.04.001_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.diabres.2018.01.031","article-title":"Correlations of the glycemic variability with oxidative stress and erythrocytes membrane stability in patients with type 1 diabetes under intensive treatment","volume":"144","author":"Rodrigues","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-023-01770-2","article-title":"Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes","volume":"22","author":"Tynj\u00e4l\u00e4","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.001_bib40","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2337\/dc09-0109","article-title":"Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes","volume":"32","author":"Kilpatrick","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.001_bib41","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/dc15-1188","article-title":"Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis","volume":"38","author":"Gorst","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib42","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1463-1326.2011.01395.x","article-title":"A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations","volume":"13","author":"Evans","year":"2011","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcjd.2025.01.001","article-title":"Glycemic management across the lifespan for people with type 1 diabetes: a clinical practice guideline","volume":"49","author":"Halperin","year":"2025","journal-title":"Can J Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.001_bib44","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.2337\/dc26-S007","article-title":"7. diabetes technology: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.001_bib45","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.90295.2008","article-title":"Insulin as a physiological modulator of glucagon secretion","volume":"295","author":"Bansal","year":"2008","journal-title":"Am J Physiol Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/dom.15297","article-title":"The glycaemic roller coaster phenomenon in type 1 diabetes","volume":"26","author":"Christensen","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib47","doi-asserted-by":"crossref","first-page":"E891","DOI":"10.1152\/ajpendo.00628.2020","article-title":"Importance of the route of insulin delivery to its control of glucose metabolism","volume":"320","author":"Edgerton","year":"2021","journal-title":"Am J Physiol Endocrinol Metabol"},{"key":"10.1016\/j.ecl.2026.04.001_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1456195","article-title":"Growth hormone\/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin","volume":"15","author":"Yuen","year":"2024","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.001_bib49","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2337\/dc11-1833","article-title":"The association between IGF-I and insulin resistance","volume":"35","author":"Friedrich","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1900\/RDS.2020.16.24","article-title":"Insulin-like growth factor and its therapeutic potential for diabetes complications mechanisms and metabolic links: a review","volume":"16","author":"Biadgo","year":"2020","journal-title":"Rev Diabet Stud"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.001_bib51","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1210\/jc.2009-0378","article-title":"Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes","volume":"94","author":"Salgin","year":"2009","journal-title":"J Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41574-019-0280-9","article-title":"The effects of growth hormone on adipose tissue: old observations, new mechanisms","volume":"16","author":"Kopchick","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12929-017-0357-5","article-title":"Role of free fatty acids in endothelial dysfunction","volume":"24","author":"Ghosh","year":"2017","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db10-0328","article-title":"Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes","volume":"60","author":"Schauer","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-nutr-071812-161201","article-title":"Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose","volume":"34","author":"Hayes","year":"2014","journal-title":"Annu Rev Nutr"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.001_bib56","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc18-1091","article-title":"Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metabol"},{"key":"10.1016\/j.ecl.2026.04.001_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1520313","article-title":"Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?","volume":"15","author":"Resnick","year":"2025","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tem.2025.06.004","article-title":"Targeting cardiometabolic risk in type 1 diabetes through incretin physiology","volume":"37","author":"Frampton","year":"2026","journal-title":"Trends Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib62","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1744666X.2025.2537446","article-title":"Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease","volume":"21","author":"Kugathasan","year":"2025","journal-title":"Expet Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.001_bib63","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/dom.16332","article-title":"Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: potential benefits and risks","volume":"27","author":"Rajab","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib64","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1038\/s41467-025-65951-1","article-title":"Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial","volume":"16","author":"Snaith","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib65","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/pedi.12493","article-title":"The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis","volume":"18","author":"Al Khalifah","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/dia.2014.0190","article-title":"Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis","volume":"17","author":"Liu","year":"2015","journal-title":"Diabetes Technol Therapeut"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.001_bib67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib68","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diacare.28.7.1562","article-title":"The effect of rosiglitazone on overweight subjects with type 1 diabetes","volume":"28","author":"Strowig","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819890527","article-title":"A review of sotagliflozin for use in type 1 diabetes","volume":"10","author":"Nuffer","year":"2019","journal-title":"Therapeutic Advances in Endocrinology"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.001_bib70","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.001_bib71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fendo.2020.00553","article-title":"Effects of sodium-glucose cotransporter inhibitor\/glucagon-like peptide-1 receptor agonist add-on to insulin therapy on glucose homeostasis and body weight in patients with type 1 diabetes: a network meta-analysis","volume":"11","author":"Kim","year":"2020","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.001_bib72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s13300-017-0282-3","article-title":"Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ecl.2026.04.001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1550938","article-title":"The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes","volume":"16","author":"Alhowiti","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2026.04.001_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.975880","article-title":"Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus","volume":"14","author":"Tan","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ecl.2026.04.001_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.ecl.2026.04.001_bib76","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2016.08.022","article-title":"The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis","volume":"121","author":"Guo","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib77","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tem.2019.11.007","article-title":"Reducing type 1 diabetes mortality: role for adjunctive therapies?","volume":"31","author":"Snaith","year":"2020","journal-title":"Trends Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.001_bib78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2024.0050","article-title":"Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Therapeut"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.001_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.mayocp.2024.07.006","article-title":"Effect of tirzepatide on body weight and diabetes control in adults with type 1 diabetes and overweight or obesity","volume":"100","author":"Rivera Gutierrez","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ecl.2026.04.001_bib80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/DMSO.S141700","article-title":"Adjunctive therapy for glucose control in patients with type 1 diabetes","volume":"11","author":"Harris","year":"2018","journal-title":"DMSO"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.001_bib81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/diacare.20.3.248","article-title":"Acarbose in the treatment of type I diabetes","volume":"20","author":"Hollander","year":"1997","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib82","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2337\/dc24-0212","article-title":"Combination SGLT2 inhibitor and glucagon receptor antagonist therapy in type 1 diabetes: a randomized clinical trial","volume":"48","author":"Boeder","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.001_bib83","article-title":"Dorzagliatin: a breakthrough glucokinase activator coming on board to treat diabetes mellitus","volume":"16","author":"Raju","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.001_bib84","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/pharmaceutics14061180","article-title":"Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective","volume":"14","author":"Aberer","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.001_bib85","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s00125-017-4364-6","article-title":"A new perspective on metformin therapy in type 1 diabetes","volume":"60","author":"Livingstone","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.001_bib86","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1445-5994.1991.tb01375.x","article-title":"Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus","volume":"21","author":"Mclntyre","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.001_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MED.0000000000000940","article-title":"Adjunctive diabetes therapies and cardiovascular protection in type 1 diabetes: tackling the challenging Tchaikovsky piece","volume":"33","author":"Wang","year":"2026","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.001_bib88","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/13543784.2022.2159806","article-title":"Recent developments in adjunct therapies for type 1 diabetes","volume":"31","author":"Timmons","year":"2022","journal-title":"Expet Opin Invest Drugs"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.001_bib89","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.001_bib90","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.001_bib91","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1210\/clinem\/dgac704","article-title":"GLP-1 receptor agonists and SGLT-2 inhibitors as adjuncts to insulin in type 1 diabetes: benefits and concerns","volume":"108","author":"Dimitriadis","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.001_bib92","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metabol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:08:00Z","timestamp":1786068480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000228"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Insulin","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}